Effectiveness and cost-effectiveness of reactive, targeted indoor residual spraying for malaria control in low-transmission settings: a cluster-randomised, non-inferiority trial in South Africa

David Bath*, Jackie Cook*, John Govere, Phillemon Mathubula, Natasha Morris, Khombulani Hlongwana, Jaishree Raman, Ishen Seocharan, Alpheus Zitha, Matimba Zitha, Aaron Mabuza, Frans Mbokazi†, Elliot Machaba, Erik Mabunda, Eunice Jamesboy, Joseph Biggs, Chris Drakeley, Devanand Moonasar, Rajendra Maharaj, Maureen Coetze, Catherine Pitt†, Immo Kleinschmidt‡

Summary

Methods This cluster-randomised, open-label, non-inferiority trial compared reactive, targeted IRS with standard IRS practice in northeastern South Africa over two malaria seasons (2015–17). In standard IRS clusters, programme managers conducted annual mass spray campaigns prioritising areas using historical data, expert opinion, and other factors. In targeted IRS clusters, only houses of index cases (identified through passive surveillance) and their immediate neighbours were sprayed. The non-inferiority margin was 1 case per 1000 person-years. Health service costs of real-world implementation were modelled from primary and secondary data. Incremental costs per disability-adjusted life-year (DALY) were estimated and deterministic and probabilistic sensitivity analyses conducted. This study is registered with ClinicalTrials.gov, NCT02556242.

Findings Malaria incidence was 0.95 per 1000 person-years (95% CI 0.58 to 1.32) in the standard IRS group and 1.05 per 1000 person-years (0.72 to 1.38) in the targeted IRS group, corresponding to a rate difference of 0.10 per 1000 person-years (−0.38 to 0.59), demonstrating non-inferiority for targeted IRS (p<0.0001). Per additional DALY averted, targeted IRS saved US$7845 (2902 to 64 907), giving a 94–98% probability that switching to targeted IRS would be cost-effective relative to plausible cost-effectiveness thresholds for South Africa ($2637 to $3557 per DALY averted). Depending on the threshold used, targeted IRS would remain cost-effective at incidences of less than 2.0–2.7 per 1000 person-years. Findings were robust to plausible variation in other parameters.

Interpretation Targeted IRS was non-inferior, safe, less costly, and cost-effective compared with standard IRS in this very-low-transmission setting. Saved resources could be reallocated to other malaria control and elimination activities.

Introduction

The mass scale-up of malaria control interventions in endemic countries has driven major reductions in malaria morbidity and mortality over the past two decades. From 2000 to 2010, it has plateaued since.1 Global malaria funding fell from $3.2 billion in 2017 to $3.0 billion in 2019, well below the estimated $5.6 billion required annually to remain on track towards the WHO global malaria strategy targets.1 Widespread and increasing insecticide resistance has compromised the effectiveness of low-cost, pyrethroid-based vector control.2 The substantially higher costs of vector control with new or repurposed insecticides to address resistance2,4 add considerably to budgetary challenges. More efficient strategies are therefore required to reduce malaria transmission. Where transmission is already very low, universal application of mass interventions might be unwarranted and unsustainable. Modelling studies suggest that targeting interventions to areas where there
is evidence of recent malaria transmission is less costly and might be similarly effective compared with blanket strategies.9–11 Evidence from randomised trials shows that adding reactive, targeted interventions to existing population-wide routine interventions can be effective in further reducing malaria in low-transmission settings.12–14 However, no study has investigated whether widespread deployment of malaria interventions, such as indoor residual spraying (IRS), can be safely replaced by reactive, targeted interventions.

IRS is recommended as a primary malaria vector control method by WHO, has been adopted as policy by national malaria control programmes in 42 African countries,1 and has contributed substantially to reducing malaria in many countries, including South Africa.9–16 IRS consists of the application of insecticide to the interior walls of houses at least once per year, usually by seasonal spray personnel. Training, organising, and supervising sprayers can be logistically challenging and result in poor quality insecticide application and inadequate spray coverage.17 More judicious deployment of IRS could therefore achieve comparable effectiveness at lower cost in low-transmission settings. We aimed to assess the non-inferiority, cost, and cost-effectiveness of reactive, targeted IRS compared with standard IRS.

Methods
Study design and clusters
We did a cluster-randomised, open-label, non-inferiority trial in a low-transmission area of northeastern South Africa. Malaria transmission is low in South Africa and confined to border districts of the three northeastern provinces of Mpumalanga, Limpopo, and KwaZulu-Natal. From 2010 to 2014, an annual mean of 8781 cases was recorded nationally, of which a high proportion were imported.20 The primary vector is Anopheles arabiensis,21 and Plasmodium falciparum accounts for nearly all cases.1 IRS has been the primary malaria control strategy in South Africa since 1945.22 At the time of our study, pyrethroid insecticides were used for painted surfaces and dichloro-diphenyl-trichloroethane (DDT) for the relatively small proportion of surfaces that are unpainted.23

Malaria is notifiable by legal statute in South Africa. In malaria risk areas, clinical guidelines require all febrile patients presenting at (public and private) health facilities to be tested for malaria by rapid diagnostic tests (First Response Malaria Ag P falciparum HRP2 Test; Premier Medical Corporation; Mumbai, India) or microscopy. Uncomplicated malaria cases are treated with artemether-lumefantrine.24 In 2019, single low dose primaquine in addition to artemisinin-based combination treatment was introduced in South Africa to reduce onward transmission.25 Intravenous artesunate is used to treat severe malaria. Health workers classify cases as imported if the onset of symptoms occurred 7–30 days after travel to a malaria endemic area outside the country.26 All deaths of people diagnosed with malaria are investigated by a clinician affiliated with the provincial malaria control programmes.
This study took place between Aug 1, 2015, and July 31, 2017, in the predominantly rural subdistricts of Bushbuckridge in Mpumalanga province and Ba-Phalaborwa in Limpopo province (figure 1). In the study area, malaria incidence ranges between fewer than 1 case per 1000 person-years and 5 cases per 1000 person-years, and malaria is mostly locally acquired and seasonal between October and May. Neither pyrethroid nor DDT resistance have been reported in the trial provinces.

Census wards were mapped and formed into clusters comprising populations of about 50 000–100 000 people. To be eligible for inclusion in the trial, clusters required a history of local cases in at least one year in the 5 years before the trial (Aug 1, 2010–July 31, 2015). Wherever possible, clusters were separated by natural boundaries or uninhabited space. Around 400 000 people resided within the trial clusters, the majority in Mpumalanga province (72%).

The trial’s objective was to determine whether targeted IRS is non-inferior to the standard strategy, standard IRS, within a specified margin of non-inferiority, using passively reported malaria incidence as the primary outcome. A non-inferiority margin of 1 case per 1000 person-years was chosen; a greater difference in incidence between study groups would be important because South Africa’s malaria elimination plan aimed to reduce incidence in all areas to below this threshold.

Figure 1: Study location
(A) Location of trial provinces. (B) Location of clusters within trial provinces. (C) Allocation of clusters to study groups within Mpumalanga. (D) Allocation of clusters to study groups within Limpopo. IRS=indoor residual spraying.
Articles

Ethics approvals were provided by institutional review boards at the London School of Hygiene & Tropical Medicine (7396-1), University of Witwatersrand (M140762), and Mpumalanga and Limpopo Provincial Departments of Health. An amendment detailing minor changes to the trial protocol was submitted on Oct 7, 2015 (appendix p 16), and ethics approval received on Dec 10, 2015. Community consent was sought through public meetings and discussions with ward councillors. During case investigation visits, written informed consent was obtained from householders. Independent trial steering and data safety monitoring committees oversaw the trial.

Randomisation and masking
Clusters were randomly assigned (1:1) to receive either standard IRS or targeted IRS using restricted randomisation to balance study groups on pre-existing characteristics that might have been associated with the trial outcome. Restriction criteria were mean malaria incidence between Aug 1, 2010, and July 31, 2015 (obtained from the provincial reporting system), province, population size, proportion of households sprayed with IRS in 2014, population density, and total length of streams and rivers. The allocation of clusters to study groups was finalised at a randomisation ceremony attended by ward councillors. Blinding of communities or research personnel to study groups was not possible; however, data analysis was masked by labelling the groups as A and B.

Procedures
The reference group, standard IRS, comprised the standard practice of annual mass spray campaigns by the provincial malaria control programmes, using either DDT or the pyrethroids deltamethrin (Bayer; Isando, South Africa) or α-cypermethrin (Efekto; Isando, South Africa). Spray training commenced in August, before the start of the malaria season, and spraying continued until December in both years. Following standard procedures, programme managers prioritised at-risk areas, such as those close to rivers and streams, on the basis of the number of malaria cases in the previous season, malaria control programme expert opinion, and available budget. Around a third of households in standard IRS clusters were sprayed annually through this informal targeting process. Spray operations were led by environmental health practitioners, who trained teams of seasonal contract sprayers over a 2-week period.

Confirmed malaria cases at health facilities are reported to the provincial malaria control programme within 24 h, triggering a case investigation. During the study, the provincial malaria control programme contacted the study coordinator to determine whether the case was imported or locally acquired, following standard guidelines. If confirmed as locally acquired, the index case house was sprayed only if it had not already been sprayed during the annual spray round. Any household member reporting fever was tested using a malaria rapid diagnostic test and referred for treatment to the nearest health facility if positive.

In the intervention group, targeted IRS, no annual mass spray campaigns were done. Case investigations were triggered in the same way as in standard IRS clusters; however, case investigation teams were employed by the trial. In addition to case investigation activities, the teams sprayed the interiors of locally acquired index case houses and up to eight neighbouring houses (around 50 structures) within 200 m with deltamethrin, regardless of wall type, subject to consent of householders. DDT was considered unsuitable for targeted IRS, because most houses in the study area have painted surfaces. Malaria testing and referral was identical to standard IRS clusters. Further details of the interventions are provided in the appendix (pp 2–5).

To verify the quality of spray application, susceptible adult A. arabiensis laboratory colony mosquitoes maintained at the Limpopo Malaria Control Programme insectary in Tzaneen were used for standard cone bioassay testing within 2–4 weeks of spraying in a random sample of households in the targeted IRS group. Standard IRS was intended to represent standard practice, so no additional quality checks were done.

Case investigation data were collected on handheld tablet computers using an application (Mobenzi Researcher) developed for the trial, uploaded in real time using cellular network to a cloud-based server, and validated and analysed using Microsoft Excel 2016 and Stata version 15.

Outcomes
The primary outcome, malaria incidence, was recorded through passive case detection at all health facilities within the subdistrict, as reported to the malaria control programme. Clinical malaria was diagnosed if the patient presented with a fever (axillary temperature ≥37.5°C) or history of fever (in the past 48 h), in the presence of parasitaemia confirmed by rapid diagnostic test or microscopy. Cases classified as imported were excluded from analysis. The trial data safety monitoring committee assessed reports of delays between diagnosis of cases and spraying in the targeted IRS group, and numbers of malaria cases and deaths between study groups to detect any unexpected increase in the targeted IRS group. Reports of malaria-associated deaths were submitted by the principal investigator to the data safety monitoring committee immediately after the provincial health department completed its investigation.

An endline cross-sectional survey was done from June 12 to Aug 16, 2017, to assess additional secondary
outcomes, including household compliance, population attitudes to IRS, and serological markers. The proportion of structures targeted for IRS that were not sprayed and the reasons why structures were not sprayed, both secondary outcomes of the trial, were not consistently collected and hence not reported. Testing for insecticide resistance could not be done, because collection of sufficient mosquitoes for standard tests proved impossible.

**Statistical analysis**

For sample size calculations, mean incidence of locally acquired malaria in the reference group was assumed to be 2·2 per 1000 person-years on the basis of historical data. Assuming a coefficient of variation between clusters of 0·5, the trial required 31 clusters per group (62 in total) of 6000 people each over 2 years (12000 person-years per cluster) for 80% power at two-sided 5% (2·5% one-sided) significance to show non-inferiority within a margin of 1 case per 1000 person-years. 32

The primary outcome, malaria incidence per cluster, was calculated from local cases recorded at health facilities and the cluster population recorded in the 2011 national census, projected forward. Cases were allocated to clusters on the basis of the place of residence provided by patients at the time of diagnosis and confirmed during case investigations. Incidence by group was calculated as the mean of the cluster incidences allowing for the clustered design. To assess non-inferiority, the incidence rate difference between study groups was estimated using linear regression on the cluster incidences with and without adjustment for province. Two-sided 95% CIs, corresponding to one-sided 97·5% intervals, and two-sided 90% CIs, corresponding to one-sided 95% intervals, were calculated as standard for non-inferiority tests. The upper limit of the CI of the difference in rates between study groups was compared with the prespecified margin of non-inferiority. p values indicate the probability of obtaining the given result by chance if the true rate difference is greater than the specified non-inferiority margin—ie, more than 1 case per 1000 person-years. Poisson regression adjusting for province was used to calculate rate ratios for cost-effectiveness analyses. 33

**Cost-effectiveness analysis**

Resource use and cost of each resource (ie, unit cost) were collected to model the real-world cost for the provincial malaria control programme to implement either standard IRS or targeted IRS as standard practice. Costs were estimated for each strategy using a combination of top-down and bottom-up costing. 34 The focus was on economic costs, which reflect the full value of all resources used; however, almost all economic costs were also financial costs, meaning they involved monetary payment. A health services perspective was adopted, which included the costs of spraying, case investigations, training, supervision, diagnosis, and treatment; costs borne by households were excluded due to lack of data. Set-up costs for targeted IRS and recurrent costs for standard IRS and targeted IRS were estimated. Costs for the provincial malaria control programme to set up targeted IRS, including training, were annualised assuming a useful life of 3 years. Costs were estimated for Mpumalanga province only (where 49 of the 62 clusters were located), because detailed accounts from the Limpopo Malaria Control Programme were unavailable. Research costs were excluded.

Where implementation costs incurred during the trial were expected to differ from real-world implementation outside a trial, cost estimates were adjusted to best approximate real-world implementation. All resources were costed using unit costs from the Mpumalanga Malaria Control Programme, even where the trial obtained them (for targeted IRS) at a different unit cost. It was assumed that implementation of targeted IRS would not change malaria control programme management and overheads, and that environmental health practitioners leading the annual mass spray campaigns would remain employed under targeted IRS.

The cost per case diagnosed and treated was assumed to be the same under either strategy and estimated from available secondary data (appendix pp 6–8). 35–37 Costs were estimated for a standardised population of 100 000 in constant 2017 US$. 38 Details of costing methods are provided in the appendix (pp 9–13).

The incremental cost savings per disability-adjusted life-year (DALY) incurred by targeted IRS compared with standard IRS were calculated to determine whether switching to targeted IRS would be cost-effective. This formulation differs from (but is equivalent to) the typical presentation of incremental cost per DALY averted, because targeted IRS is designed to be less costly but potentially (slightly) less effective than its comparator. Incremental cost-effectiveness ratios (ICERs) were compared with the lowest ($2637, 43% of gross domestic product [GDP] per capita) and highest ($3557, 58% of GDP per capita) of four cost-effectiveness thresholds, 39 which reflect the benefits forgone in withdrawing

| Standard IRS group | Targeted IRS group |
|--------------------|--------------------|
| Number of clusters | 31                 | 31                 |
| Mpumalanga         | 24                 | 25                 |
| Limpopo            | 7                  | 6                  |
| Mean cluster population (SD) | 6102 (3254) | 6588 (2225) |
| Mean number of households per cluster (SD) | 1534 (802) | 1619 (545) |
| Mean population density per cluster (SD) | 1095 (447) | 1091 (510) |
| Mean annual local malaria case incidence per 1000 population for 2010-15 (SD) | 1.05 (0.89) | 0.88 (0.89) |
| Mean percentage of households sprayed by IRS in the previous year (SD) | 41.4% (29.3) | 38.7% (23.2) |

IRS=indoor residual spraying.
resources from an existing intervention in South Africa. Cost-effectiveness results were estimated overall (ie, for both years combined) and by year.

A decision tree was used to model costs and health outcomes over a lifetime horizon (appendix p 14). DALYs were modelled as the sum of years of life lost and years of life lived with disability using a discount rate of 3% and no age weighting (appendix p 15).49

The impact of uncertainty in individual input parameters on cost-effectiveness was explored through deterministic sensitivity analysis by varying parameters individually across plausible value ranges. Probabilistic sensitivity analysis was done to explore the combined impact of parameter uncertainty. Proportions were assumed to follow beta distributions; non-negative parameters, such as costs, were assumed to be gamma distributed. By use of Monte Carlo simulation, 10 000 samples were drawn from the parameter distributions and used to calculate incremental costs and effects, which were plotted on the cost-effectiveness plane alongside cost-effectiveness thresholds. Mean ICERs were calculated as the mean incremental cost across iterations divided by the mean incremental DALYs across iterations. 95% credible intervals were calculated as percentiles of the ICER distribution. Using cost-effectiveness acceptability curves,41 the probability that switching from standard to targeted IRS would be cost-effective at different thresholds was calculated.

Malaria incidence at which the more cost-effective strategy would change was calculated in a threshold analysis. For targeted IRS, it was assumed that the cost of insecticide, as well as diagnostic and treatment costs, would increase in proportion to the number of cases, but that other resources associated with case investigations (case investigators, equipment, and transport costs) would remain fixed. For standard IRS, only diagnostic and treatment costs were assumed to vary with the number of cases; all other resources would remain fixed. Incidence was varied until the ICER (for the 2 years combined) equalled each of the cost-effectiveness thresholds. Details of model parameters are provided in the appendix (pp 6–8). This study is registered with ClinicalTrials.gov, NCT02556242.

| Group size | Standard IRS | Targeted IRS | Total | Standard-targeted rate difference (95% CI) | Incremental cost (% standard IRS) |
|------------|--------------|--------------|-------|-------------------------------------------|----------------------------------|
| Number of clusters | 31 | 31 | 62 | | |
| Study population | 189 150 | 204 237 | 393 387 | | |

**Year 1**

| | Solar | Targeted IRS | Total | Standard-targeted rate difference (95% CI) | Incremental cost (% standard IRS) |
|-----------------|------|--------------|-------|-------------------------------------------|----------------------------------|
| Number of local malaria cases | 7 | 13 | 20 | | |
| Number of deaths | 1 | 0 | 1 | | |
| Crude incidence per 1000 person-years | 0·04 | 0·06 | 0·05 | | |
| Total economic cost per 100 000 population, constant 2017 US$ | $189 118 | $185 432 | – | – | $103 685 (−55%) |
| Economic cost per structure sprayed, constant 2017 US$ | $2·78 | $737·86 | – | – | $735·07 (26·409%) |

**Year 2**

| | Solar | Targeted IRS | Total | Standard-targeted rate difference (95% CI) | Incremental cost (% standard IRS) |
|-----------------|------|--------------|-------|-------------------------------------------|----------------------------------|
| Number of local malaria cases | 304 | 381 | 685 | | |
| Number of deaths | 11 | 9 | 20 | | |
| Crude incidence per 1000 person-years | 1·64 | 1·94 | 1·74 | | |
| Total economic cost per 100 000 population, constant 2017 US$ | $178 861 | $90 733 | – | – | $88 127 (−49%) |
| Economic cost per structure sprayed, constant 2017 US$ | $3·75 | $26·20 | – | – | $22·45 (598%) |

**Total**

| | Solar | Targeted IRS | Total | Standard-targeted rate difference (95% CI) | Incremental cost (% standard IRS) |
|-----------------|------|--------------|-------|-------------------------------------------|----------------------------------|
| Number of local malaria cases | 311 | 394 | 705 | | |
| Number of deaths | 12 | 9 | 21 | | |
| Crude incidence per 1000 person-years | 0·82 | 0·96 | 0·90 | | |
| Malaria case incidence* per 1000 person-years (95% CI) | 0·95 (0·58 to 1·32) | 1·05 (0·72 to 1·38) | – | 0·10 | |
| Total economic cost per 100 000 population, constant 2017 US$ | $184 319 | $88 258 | – | – | $96 061 (−52%) |
| Economic cost per structure sprayed, constant 2017 US$ | $3·19 | $49·23 | – | – | $46·04 (1444%) |

IRS=indoor residual spraying. *Mean of cluster incidences. †Non-inferiority p value <0·0001.

Table 2: Local malaria cases, crude incidence, and cost, by year and study group.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Results
The study profile is provided in the appendix (p 17). Characteristics at baseline are summarised in table 1. During the 2-year trial period, 1030 malaria cases were recorded, of which 705 (68%) were classified as locally acquired, corresponding to a crude incidence of 0·90 local cases per 1000 person-years (table 2). In Limpopo, incidence was 1·88 cases per 1000 person-years and in Mpumalanga 0·65 cases per 1000 person-years. Annual incidence was 0·05 per 1000 person-years (n=20) in year 1 and 1·74 per 1000 person-years (n=685) in year 2. Incidence by cluster varied from zero cases (seven clusters, all in Mpumalanga: three in the standard IRS group and four in the targeted IRS group) to more than 3 cases per 1000 person-years (four clusters, of which three were in Limpopo: two in the standard IRS group and two in the targeted IRS group). Case incidence varied substantially over time, peaking in May, 2017, when 54% (n=383) of all locally acquired cases occurred (appendix p 18). Median age of individuals with locally acquired malaria was 27 years (IQR 10–37; range 0–91), and 373 (53%) of 705 cases occurred in men.

There were 21 deaths (12 in the standard IRS group and nine in the targeted IRS group) associated with locally acquired malaria during the study period, corresponding to a case fatality rate of 3·0% (table 2). The median age at death was 40 years (IQR 34–53; range 22–66). The most common factors contributing to death were late presentation (n=8) and patients not being tested for malaria at first presentation (n=5). No other serious adverse events were reported.

In Mpumalanga, 128 519 structures (broadly defined as individual rooms within a house or outbuilding) were sprayed in standard IRS clusters in the first year and 90 196 in the second; in targeted IRS clusters, 132 and 6163 structures were sprayed in the same periods. In Limpopo, 150 structures were sprayed in targeted IRS clusters in the first year and 1622 in the second; data on the number of structures sprayed in standard IRS clusters were not available for Limpopo (appendix p 17). In the targeted IRS group, teams sprayed on average 3·7 neighbouring houses per investigation, despite repeat visits. Case investigation teams reported that, due to scattered settlement patterns, index case houses often had fewer than eight houses within 200 m. Cone bioassay testing done on 14 sprayed structures in the targeted IRS group reported an overall 24-h mosquito mortality of 99·5% (n=420), providing assurance of satisfactory insecticide application. Results of the endline survey are reported in the appendix (p 19).

Malaria case incidence was 0·95 per 1000 person-years (95% CI 0·58 to 1·32; n=311) in the standard IRS group and 1·05 per 1000 person-years (95% CI 0·72 to 1·38; n=394) in the targeted IRS group (table 2); the rate difference was 0·10 (95% CI 0·38 to 0·59), equivalent to one extra case for every 10 000 people in the targeted IRS group (figure 2). There was strong evidence of
non-inferiority of targeted IRS compared with standard IRS within the predefined margin of 1 case per 1000 person-years at the 2·5% one-sided significance level (p=0·0001). Adjusted for province, the rate difference was 0·14 (95% CI –0·27 to 0·55; figure 2). Further sensitivity analysis is reported in the appendix (p 20). In year 1, there was strong evidence that targeted IRS was non-inferior to standard IRS (adjusted rate difference 0·04, 95% CI –0·07 to 0·16; p=0·0001). For year 2, the 95% CIs crossed the non-inferiority margin for both the crude and adjusted rate differences, but the 90% CI (equivalent to 5% one-sided significance level) for both estimates remained below the non-inferiority threshold (adjusted rate difference 0·24, 95% CI –0·54 to 1·03, 90% CI –0·41 to 0·90; p=0·058; appendix p 21).

The average annual economic cost was $88 258 per 100 000 population for targeted IRS, 52% less than standard IRS ($184 319; table 2). Targeted IRS cost less, because it involved spraying fewer structures (around 3% of the structures sprayed in standard IRS), it did not use contract sprayers, and it used substantially less insecticide, transport, and equipment. Except for contract sprayers, personnel costs were similar across the two groups. Malaria treatment costs comprised a very small proportion of total costs under standard (0·9%) and targeted (2·3%) IRS. Further results by cost component are reported in the appendix (p 22).

Across the 2-year trial, targeted IRS saved $7845 (95% CI 2902–64907) for each additional DALY incurred relative to standard IRS (figure 3). In year 1, when incidence was lower, targeted IRS saved $35 149 for each additional DALY incurred; the lower bound of the 95% CI was $6481 and at the higher bound targeted IRS was dominant—ie, less expensive and more effective than standard IRS. In year 2, when incidence was higher, targeted IRS saved $3869 (95% CI $1371–$50 689) per DALY incurred. At both cost-effectiveness thresholds ($2637 and $3557), targeted IRS would be considered cost-effective across the trial period and in each of the 2 years (figure 3)—ie, the cost savings from switching from standard to targeted IRS would be expected to generate greater net health benefits if invested elsewhere in the health system. At the incidence observed in the trial, targeted IRS would have a 94–98% probability of being the cost-effective choice at either cost-effectiveness threshold (figure 3; appendix p 23).

The finding that targeted IRS was cost-effective across the 2-year trial period is robust to plausible variation in all
individual parameters evaluated (figure 4) and to re-analysis on the basis of Mpumalanga-specific incidence and rate ratios (appendix p 25). Year 1 results are similarly robust. If implemented in year 2 only, when incidence was higher, targeted IRS would not be cost-effective with respect to either of the cost-effectiveness thresholds if the rate ratio were at the upper bound of the 95% CI; targeted IRS would be cost-effective at the lower but not the higher threshold for plausible variation in six of the eight other parameters explored (figure 4). If all parameters except incidence remained constant, we estimated that targeted IRS would remain the preferred strategy up to an incidence of 2.0–2.7 cases per 1000 person-years, using the higher and the lower cost-effectiveness thresholds.

Discussion
This study has shown that reactive, targeted IRS in response to index cases was non-inferior to mass annual IRS campaigns, which prioritise areas selected on the basis of historical information and expert opinion, within a margin of 1 case per 1000 person-years in this low-transmission setting in South Africa. In this context, changing from standard to targeted IRS would be a more efficient use of scarce malaria control programme resources, while providing non-inferior malaria protection. By adopting targeted IRS, the malaria control programme would make substantial savings, which could be redirected to other, potentially more efficient and life-saving malaria interventions, such as improved awareness of malaria risk among affected communities and healthcare providers, enhanced case management, surveillance, and border screening. If targeted IRS were standard practice in this setting, adoption of standard IRS (at an ICER of $7845 per DALY averted) would not be considered cost-effective. However, replacing the existing standard IRS intervention that has been in place for many years would be politically and socially sensitive and would require caution and vigilance to avoid resurgence in cases.

These findings were generally robust to plausible changes in key parameters and are conservative in several ways. Cost savings would have been greater if we had included the substantial increases in insecticide costs that are expected when insecticide resistance necessitates a switch to more expensive next generation insecticides. Although South Africa’s overall malaria case fatality rate was 0.79% in the first study year and 1.06% in the second, our cost-effectiveness estimates were based on the observed study case fatality rate of 3.0%. Although mortality was similar in the two study groups, at lower overall case fatality rates, targeted IRS would be more cost-effective because any additional cases (relative to standard IRS) would result in fewer deaths and DALYs. Targeted IRS was much more cost-effective in year 1 than year 2, due to substantial between-year heterogeneity in incidence; however, targeted IRS remained the more cost-effective strategy (61–78% probability) in year 2 (appendix p 23).

In South Africa, malaria incidence often varies substantially between years. Incidence was markedly higher during the second year of this study than the first. In standard IRS clusters, fewer structures were sprayed in year 2 because the informal targeting is based partly on the (very low) malaria incidence in the preceding season. In targeted IRS clusters, more structures were sprayed in year 2 in accordance with the protocol. The increased incidence resulted in some delays to the reactive spraying, which might have caused onward transmission and an increase in case numbers. In year 2, targeted IRS remained non-inferior to standard IRS at the one-sided 5% significance level, but not at the 2.5% significance level. The finding of more marginal non-inferiority at higher incidence should be interpreted with caution, however, because the trial was not powered to demonstrate non-inferiority in individual study years.

Our study has several limitations. First, incidence was measured using passive case detection, so any asymptomatic infections that could lead to onward malaria transmission would remain undetected. In South Africa, however, the vast majority of cases are symptomatic because the population does not have partial immunity, due to low exposure to malaria parasites. Additionally, self-medications is unlikely because the informal sector does not sell antimalarials. We therefore consider passive case detection robust in this setting. Second, possible misclassification of local cases as imported might have reduced the impact of the targeted IRS strategy because reactive spraying was only done in response to locally acquired cases. Third, in the targeted IRS group, fewer than half of the intended eight neighbouring houses were sprayed on average. Although the intervention would be more expensive at higher coverage, it might also be more effective. Fourth, costs were only estimated forMpumalanga province, as such information was not available from Limpopo; however, results are robust to wide variation in unit costs and resource use (figure 4).

Fifth, we did not quantify the inconvenience or potential secondary benefits (such as insect control) of receiving IRS or the costs to households of experiencing and seeking treatment for malaria; however, we expect these factors to have a relatively small incremental impact. Finally, we assumed that real-world implementation of targeted IRS by the provincial malaria control programme would achieve similar effectiveness as the trial without additional management and supervision. We consider this assumption reasonable because malaria control programme managers (who would deliver targeted IRS in a future implementation) receive similar remuneration to the trial managers who delivered targeted IRS in the study, and because we conservatively assumed that staff managing the spray programme would be retained (appendix pp 9–13).

This trial is the first to directly compare reactive IRS with annual, mass IRS campaigns. Previous studies have evaluated the effect of adding reactive targeted
interventions, including IRS and drug administration, to routine population-wide measures, to further reduce or eliminate malaria.4,5 A trial in Namibia showed effective reduction of malaria incidence through reactive focal mass drug administration and reactive focal IRS, alone and in combination, when added to standard IRS.46 Our trial is unique in using a non-inferiority design to assess whether replacing annual IRS campaigns with reactive IRS targeting at-risk neighbourhoods would be safe and prevent malaria from surging out of control. As governments seek more sustainable strategies to enable the best use of scarce resources, non-inferiority trials could become more commonplace.

We expect our findings to be generalisable to very-low-transmission settings with well functioning surveillance systems. The reference, standard IRS, already uses informal targeting, prioritising areas on the basis of the resources available, local information, and malaria incidence in the previous year. Because many countries have adopted similar targeting strategies, our findings regarding a cost-effective, data-driven, alternative strategy are expected to be widely relevant. The reactive targeted strategy we evaluated relies on well functioning surveillance systems; such systems are considered essential by WHO for countries pursuing malaria elimination.50,51 Our results showed that targeted IRS would cease to be cost-effective in South Africa above an incidence of 2·0–2·7 per 1000 person-years, depending on the cost-effectiveness threshold used. We would therefore only recommend this strategy when transmission is proven to be very low through reliable case reporting.

This study highlighted weaknesses in malaria control that would benefit from investment, which could be achieved with the savings obtained from targeted IRS. The observed case fatality rate was high and indicated the need for appropriate interventions. Despite good knowledge about malaria reported in a household survey, some of the deaths during the study period were attributed to late presentation to a health facility, which could reflect low care seeking in populations in which malaria is rare.59 Lack of malaria testing at first presentation to health facilities that, on some death reports, and might be associated with Lack of malaria testing at first presentation was also stated have adopted similar targeting strategies, our findings incidence in the previous year. Because many countries resources available, local information, and malaria informal targeting, prioritising areas on the basis of the systems. The reference, standard IRS, already uses transmission settings with well functioning surveillance could become more commonplace.

The commitment by heads of states in the Southern African Development Community to eliminate malaria in the region by 203057 is commendable and ambitious. Fulfilling this goal will require identification of the most cost-effective ways to allocate scarce resources in changing epidemiological contexts. The withdrawal of mass prevention efforts in an uncoordinated manner motivated solely by cost considerations would be irresponsible and risk a rebound in malaria. The strategy presented here, reactive targeting of IRS on the basis of evidence of recent transmission, was shown to be safe and highly cost-effective in a pre-elimination setting and could free up vital resources for other, life-saving malaria services. Its implementation should be cautiously considered in settings where malaria transmission is already very low, case surveillance is robust, and health systems are able to respond nimbly to resurgent outbreaks.

Contributors
AM, CD, RM, MC, and IK conceived and designed the study. IK oversaw statistical aspects of the trial. JG and DM contributed to the design of the study, and JG led its implementation. PM, AZ, and MZ supported the field implementation. AM and FM managed provincial staff in standard IRS clusters. AZ, EIM, and ERM supported provincial operations in standard IRS clusters. KH and JR led the training of field staff, supported by EJ and JB. NM delineated the clusters and produced the maps used in case investigations. IS designed and managed the trial databases. JC did the epidemiological analyses. CP designed and supervised the cost-effectiveness analysis. DB collected the cost data and did the cost and cost-effectiveness analyses. The manuscript was written by DB and JC and revised by CP and IK. MC and IK provided oversight of the study. All authors approved the final draft of the manuscript. JC and IK had full access to all the epidemiological data in the study and DB had full access to all the economic data. JC and DB had final responsibility for the decision to submit for publication.

Declaration of interests
We declare no competing interests.

Data sharing
Deidentified data will be made available upon reasonable request to the corresponding author.

Acknowledgments
The trial was funded by Joint Global Health Trials (MR/L00433X/1).
MC was funded by a Department of Science and Technology–National Research Foundation Research Chairs Initiative grant (6763). IK was supported by UK Medical Research Council and UK Department for International Development under the Concordat agreement, which is part of the second European & Developing Countries Clinical Trials Partnership programme supported by the EU (MR/R010161/1). We thank and acknowledge the contribution of the residents of Bushbuckridge and Phalaborwa who participated in the study, the Mpumalanga and Limpopo Provincial Malaria Control Programmes, and the trial personnel who conducted the targeted intervention. We also thank the South Africa National Malaria Programme and members of the Steering Committee and Data Safety and Monitoring Committee for their support.
Articles

References

1. WHO. World malaria report 2020. Geneva: World Health Organization, 2020.

2. Bhattacharya S, Weiss DJ, Cameron E, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature 2015; 526: 207–11.

3. Kleinschmidt I, Bradley J, Knox TB, et al. Implications of insecticide resistance for malaria vector control with long-lasting insecticidal nets: a WHO-coordinated, prospective, international, observational cohort study. Lancet Infect Dis 2018; 18: 640–49.

4. Churruca TS, Lissenend N, Griffith JT, Worrall E, Ranson H. The impact of pyrethroid resistance on the efficacy and effectiveness of bednets for malaria control in Africa. eLife 2016; 5: 5.

5. Kafy HT, Ismail BA, Mnzava AP, et al. Impact of insecticide resistance in Anopheles arabiensis on malaria incidence and prevalence in Sudan and the costs of mitigation. Proc. Natl Acad Sci USA 2017; 114: E11267–75.

6. Mnzava AP, Knox TB, Temu EA, et al. Implementation of the global plan for insecticide resistance management in malaria vectors: progress, challenges and the way forward. Malar J 2015; 14: 173.

7. WHO. Global plan for insecticide resistance management in malaria vectors. Geneva: World Health Organization, 2012.

8. Okumu F. The paradigm of eave tubes: scaling up house improvement and optimizing insecticide delivery against disease-transmitting mosquitoes. Malar J 2017; 16: 207.

9. Drake TL, Kyaw SS, Kyaw MP, et al. Cost effectiveness and resource allocation of Plasmodium falciparum malaria control in Myanmar: a modelling analysis of bed nets and community health workers. Malar J 2015; 14: 376.

10. Chitnis N, Schapira A, Schindler C, Penny MA, Smith TA. Mathematical analysis to prioritise strategies for malaria elimination. J Theor Biol 2018; 455: 118–30.

11. Walker PG, Griffin JT, Ferguson NM, Ghani AC. Estimating the most efficient allocation of interventions to achieve reductions in Plasmodium falciparum malaria burden and transmission in Africa: a modelling study. Lancet Glob Health 2016; 4: e474–84.

12. Bonesma T, Stresman G, Baidjoe AY, et al. The impact of hotspot-targeted interventions on malaria transmission in Rachuonyo South District, Kenya: a cross-case study analysis. Value Health 2019; 22: 1026–32.

13. Eisele TP, Bennett A, Silumbe K, et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in Southern Province Zambia: a cluster-randomized controlled trial. J Infect Dis 2016; 214: 1831–39.

14. Hsiang MS, Ntuku H, Roberts KW, et al. Effectiveness of reactive focal mass drug administration and reactive focal vector control to reduce malaria transmission in the low malaria-endemic setting of Namibia: a cluster-randomised controlled, open-label, two-by-two factorial design trial. Lancet 2020; 395: 1361–73.

15. Eisele TP, Larsen D, Steketee RW. Protective efficacy of interventions for preventing malaria mortality in children in Plasmodium falciparum endemic areas. Int J Epidemiol 2010; 39 (suppl 1): 88–101.

16. Fullman N, Burstein R, Lim SS, Medlin C, Gakidou E. Nets, spray or both? The effectiveness of insecticide-treated nets and indoor residual spraying in reducing malaria morbidity and child mortality in sub-Saharan Africa. Malar J 2013; 12: 62.

17. Keating J, Locatelli A, Gebsmichael A, et al. Evaluating indoor residual spray for reducing malaria infection prevalence in Ethiopia: results from a community randomized control trial. Acta Trop 2011; 119: 107–13.

18. Sherrard-Smith E, Griffin JT, Winstink P, et al. Systematic review of indoor residual spray efficacy and effectiveness against Plasmodium falciparum in Africa. Nat Commun 2018; 9: 4982.

19. Smith Gueye C, Newby G, Gosling RD, et al. Strategies and approaches to vector control in nine malaria-eliminating countries: a cross-case study analysis. Malar J 2016; 15: 2.

20. Raman J, Morris N, Frean J, et al. Reviewing South Africa’s malaria elimination strategy (2012-2018): progress, challenges and priorities. Malar J 2016; 15: 438.

21. Brooke B, Koekemoer I, Kruger P, Urbach J, Misiani E, Coetzee M. Malaria vector control in South Africa. S Afr Med J 2013; 103: 784–88.

22. Coetzee M, Kruger P, Hunt RH, Durheim DN, Urbach J, Hansford CF. Malaria in South Africa: 110 years of learning to control the disease. S Afr Med J 2013; 103: 793–798.

23. Raman J, Allen E, Workman L, et al. Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial. Malar J 2019; 18: 209.

24. South Africa National Department of Health. Surveillance guidelines for malaria elimination and prevention of reintroduction for South Africa. National Institute for Communicable Diseases, 2012. https://www.nicd.ac.za/assets/files/Surveillance%20Guidelines%20for%20Malaria%20Elimination%20and%20Prevention%20of%20Reintroduction%20of%20Malaria%20in%20South%20Africa%20(2012).pdf (accessed Jan 22, 2021).

25. Maharaj R, Morris N, Seocharan I, et al. The feasibility of malaria elimination in South Africa. Malar J 2012; 11: 423.

26. Silal SP, Barnes KJ, Kok G, Mabuza A. Little F. Exploring the seasonality of reported treated malaria cases in Mpumalanga, South Africa. PLoS One 2013; 8: e67640.

27. Nardin I, Christian RN, Coetzee N, Koekemoer LL. DDT and pyrethroid resistance in Anopheles arabiensis from South Africa. Parasit Vectors 2013: 6: 229.

28. Brooke B. The epidemiological effect of insecticide resistance on malaria incidence—the South African experience. Communicable Diseases Surveillance Bulletin, volume 14. National Institute for Communicable Diseases, 2016. https://www.nicd.ac.za/assets/files/CommDisBull%2014(1)-Mar2016(1).pdf (accessed Jan 22, 2021).

29. Martin C, Curtis B, Fraser C, Sharp B. The use of a GIS-based malaria information system for malaria research and control in South Africa. Health Place 2002; 8: 227–36.

30. WHO. Indoor residual spraying: an operational manual for indoor residual spraying (IRS) for malaria transmission control and elimination. 2nd edn. Geneva: World Health Organization, 2015.

31. WHO. Guidelines for testing mosquito adulticides for indoor residual spraying and treatment of mosquito nets. Geneva: World Health Organization, 2006.

32. Hayes RJ, Moulton LH. Cluster randomised trials, 2nd edn. Boca Raton, FL: CRC Press, 2017.

33. Sculpher MJ, Pang FS, Manca A, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess 2004; 8: iii–iv, 1–192.

34. Cunnama L, Sinanovic E, Ramma L, et al. Using top-down and bottom-up costing approaches in LMICs: the case for using both to assess the incremental costs of new technologies at scale. Health Econ 2016; 25 (suppl 1): 53–66.

35. The Global Fund. Pooled procurement mechanism reference pricing: RDTs. The Global Fund, 2019. https://www.theglobalfund.org/media/7564/ppm_hivrdtreferencepricing_table_en.pdf (accessed April 29, 2020).

36. The Global Fund. Pooled procurement mechanism reference pricing: antimalarial medicines. The Global Fund, 2019. https://www.theglobalfund.org/media/5812/ppm_acetreferencelpricing_table_en.pdf?u=637177162070000000 (accessed April 29, 2020).

37. WHO. Health service delivery costs. World Health Organization, 2011. http://www.who.int/choice/cost-effectiveness/inputs/health_service/en/ (accessed April 29, 2020).

38. Turner HC, Lauer JA, Tran BX, Teerawattananon Y, Jit M. Adjusting for inflation and currency changes within health economic studies. Value Health 2015; 18: 1026–32.

39. Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. BMJ Glob Health 2018; 3: e000696.

40. Wilkinson T, Sculpher MJ, Claxton K, et al. The International Decision Support Initiative reference case for economic evaluation: an aid to thought. Value Health 2016; 19: 221–28.

41. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation studies in healthcare: a review and case studies. Oxford: Oxford University Press, 2006.

42. Davies C, Graffy R, Shandukani M, et al. Effectiveness of 24-h mobile reporting tool during a malaria outbreak in Mpumalanga Province, South Africa. Malar J 2019; 18: 45.
43 Dowie J, Kaltoft MK, Nielsen JB, Salkeld G. Caveat emptor NICE: biased use of cost-effectiveness is inefficient and inequitable. *F1000 Res* 2015; 4: 1078.
44 Yeomans F. IVCC in the Indo-Pacific: delivering through partnerships. IVCC, 2020. https://www.ivcc.com/market-access/ngenirs/ivcc (accessed April 29, 2020).
45 Bekolo CE, Williams TD. Adding proactive and reactive case detection into the integrated community case management system to optimise diagnosis and treatment of malaria in a high transmission setting of Cameroon: an observational quality improvement study. *BMJ Open* 2019; 9: e026678.
46 Hsiang MS, Nthahinzibali N, Kang Dufour MS, et al. Active case-finding for malaria: a three-year national evaluation of optimal approaches to detect infections and hotspots through reactive case detection in the low transmission setting of Eswatini. *Clin Infect Dis* 2020; 70: 1316–25.
47 Baltzell KA, Maglaur A, Bangu K, et al. “We were afraid of the lion that has roared next to us”; community response to reactive focal mass drug administration for malaria in Eswatini (formerly Swaziland). *Malar J* 2019; 18: 238.
48 Hast MA, Chaponda M, Muleba M, et al. The impact of three years of targeted IRS with pirimiphos-methyl on malaria parasite prevalence in a transmission area of northern Zambia. *Am J Epidemiol* 2019; 188: 2120–30.
49 Sy O, Niang EHA, Diallo A, et al. Evaluation of the effectiveness of a targeted community-based IRS approach for malaria elimination in an area of low malaria transmission of the central-western Senegal. *Parasite Epidemiol Control* 2019; 6: e00109.
50 Lourenço C, Tatem AJ, Atkinson PM, et al. Strengthening surveillance systems for malaria elimination: a global landscaping of system performance, 2015-2017. *Malar J* 2019; 18: 115.
51 WHO. A framework for malaria elimination. Geneva: World Health Organization, 2017.
52 Biggs J, Raman J, Cook J, et al. Serology reveals heterogeneity of *Plasmodium falciparum* transmission in northeastern South Africa: implications for malaria elimination. *Malar J* 2017; 16: 48.
53 Gerritsen AA, Kruger P, van der Loeff MF, Grobusch MP. Malaria incidence in Limpopo Province, South Africa, 1998-2007. *Malar J* 2008; 7: 162.
54 South Africa National Department of Health. Malaria elimination strategic plan for South Africa 2019–2023. Pretoria: South Africa National Department of Health, 2019.
55 Southern African Development Community. SADC malaria report 2017. Harare: Southern African Development Community, 2017.
56 Quan V, Hulth A, Kok G, Blumberg L. Timelier notification and action with mobile phones-towards malaria elimination in South Africa. *Malar J* 2014; 13: 151.
57 Africa Science News. SADC Heads commit to ending malaria by 2030. Africa Science News, 2018. https://africasciencenews.org/sadc-heads-commit-to-ending-malaria-by-2030/ (accessed June 22, 2020).
58 WHO. Global Health Observatory data repository. Life tables by country. World Health Organization, 2016. https://apps.who.int/gho/data/node.main.LIFECOUNTRY (accessed June 22, 2020).